Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib is a research paper published in Annals of Oncology (2023). On theSindex it has a DataRank of 1.2. It has been cited 42 times, with 26 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.564
From this paper's citation signal
Citation Network Contribution
0.664
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 26 citers.
Fundación Científica de la Asociación Española Contra el Cáncer
Grant: CLSEN20004SERR
National Cancer Institute
Grant: 1 R21 CA263400-01
National Cancer Institute
Grant: P30CA240139
Department of Veterans Affairs
Grant: 1 I01 BX005358-01A1
Instituto de Salud Carlos III
Grant: FI20/00275
Instituto de Salud Carlos III
Grant: PI22_00720
Instituto de Salud Carlos III
Grant: PI19/01271
BLRD VA
Grant: I01 BX005358
NCI NIH HHS
Grant: R21 CA263400
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 3P30CA240139-02S3
The Sylvester Cancer Center Support Grant
National Institutes of Health
Grant: 5R21CA263400-02
Novel models for functional profiling of germline SDH variants associated with cancer
NIH
Fero Foundation
GIST Cancer Research Fund
FWCI
8.41
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals